This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SALT LAKE CITY, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the 32
nd Annual J.P. Morgan Healthcare Conference, at 9:30 a.m. Pacific on January 13, 2014, at the Westin St. Francis Hotel in San Francisco, California.
The presentation will be available to interested parties through a live audio webcast accessible through a link on the investor relations section of Myriad's website at
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website:
CONTACT: Media Contact: Ron Rogers
Investor Contact: Scott Gleason